Skip to content

Two Modes of Mechanical Ventilation for Intensive Care Patients With Low Blood Oxygen Due to Breathing Difficulties

Transpulmonary Pressure During Volume Controlled Mechanical Ventilation Versus Airway Pressure Release Ventilation for Hypoxic Respiratory Failure - a Randomized Feasibility Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06140056
Enrollment
45
Registered
2023-11-18
Start date
2023-12-08
Completion date
2025-09-03
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic Respiratory Failure, Ventilators, Mechanical

Keywords

Transpulmonary pressure, Airway pressure release ventilation, Volumen controlled mechanical ventilation, Esophageal pressure, Esophageal manometry

Brief summary

The study examines individuals admitted to the intensive care unit due to breathing difficulties resulting in not getting enough oxygen into their bodies. These patient will receive mechanical ventilation and this study aims to determine how the pressure inside the lungs changes when using two different modes of mechanical ventilation. The goal is to improve management and care of breathing difficulties by gaining insight into changes in lung pressure during mechanical ventilation, as well as comparing the effectiveness of the two ventilator modes.

Detailed description

As hypoxic respiratory failure is an acute condition, this trial will enrol temporarily incompetent patients and obtain consent from the patient's next of kin and an independent medical doctor (trial guardian) as soon as possible after enrolment. When included in the study, patients will be randomized 1:1 centrally in the RedCap system, using a computer-generated concealed assignment sequence, with permuted blocks of varying sizes, to start with either the intervention (APRV) followed by control (volume controlled mechanical ventilation) or control followed by intervention. Esophageal manometry will be used as a surrogate to measure the transpulmonary pressure. Arterial blood gasses, blood samples and lung ultrasound will be used to investigate oxygenation, ventilation and aeration. Treatment targets for both groups during the study are pH \>7.20, saturation ≥ 88% and PaO2 ≥ 8.0 kPa, with FiO2 titrated as low as possible while complying to the oxygenation targets (PaO2 and saturation). Both arms start with an 'adjustment phase' where the ventilator is adjusted so the respiratory values are within the targets. The intervention adjustment phase is at least 30 minutes. The adjustments will follow standardized protocols. When the respiratory values are within range, the 'observation period begins' and no changes are made to the ventilator for 3 hours, unless it is necessary to achieve ventilatory treatment targets or deemed necessary by the treating physician. During the trial, the patient must be positioned in a supine position with the headboard elevated 0-30 degrees. After the first 'observation period', the patient is switched to the opposite ventilation mode and will go through an 'adjustment phase' and 'observation period' again. Once a patient regains competence, they will be provided with both written and oral information regarding the trial By comparing volume controlled mechanical ventilation and APRV and their transpulmonary pressures, valuable insight can be gained regarding optimal ventilation strategy for patients with hypoxic respiratory failure. Understanding how various ventilation modes influence transpulmonary pressure and their potential effects on respiratory mechanics can potentially inform designs of trials with individualized respiratory care.

Interventions

Mechanical ventilation mode

OTHERVolumen controlled mechanical ventilation

Mechanical ventilation mode

Sponsors

University Hospital Bispebjerg and Frederiksberg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to the ICU * Invasive mechanical ventilation with FiO2 ≥ 50% OR PaO2-to-FiO2 ratio \<20 kPa, including PEEP 3 5 cmH20 for at least 6 hours

Exclusion criteria

* Meeting inclusion criteria for more than 24 hours * Severe bronchospasm, defined as warranting treatment aimed at reversing this i.e. inhalation of anticholinergic or bronchodilator beyond what the patient normally use * Emphysema where treating physician judges the patient at increased risk for pneumothorax from APRV * Restrictive lung disease defined as a pre-admission diagnosis of restrictive lung disease * Undrained pneumothorax * Hemodynamic instability defined as more than 0.20 microgram/kg/min of norepinephrine or any dose of adrenaline infusion to maintain MAP ≥ 65 mmHg * Age \< 18 years * Patients who have received APRV previously during the current ICU admission * Patients in prone position within the last 24 hours

Design outcomes

Primary

MeasureTime frameDescription
Median peak transpulmonary pressureDuring the observation period; 1-6 hours after randomizationMeasured with esophageal manometry in cmH20.

Secondary

MeasureTime frameDescription
Proportion of patients with peak transpulmonary pressure > 12 cmH2ODuring observation period; 1-6 hours after randomizationMeasured with esophageal manometry
Change in peak transpulmonary pressure in cmH20During observation period; 1-6 hours after randomizationMeasured with esophageal manometry. Calculated as beginning - end of observation period
Fluctuations in transpulmonary pressure in cmH20During observation period; 1-6 hours after randomizationMeasured with esophageal manometry. Difference between peak and nadir transpulmonary pressure during respiratory cycle
Change in fluctuations of transpulmonary pressure in cmH20During observation period; 1-6 hours after randomizationMeasured with esophageal manometry. Calculated as beginning - end of observation period.
Peak FiO2 in %During observation period; 1-6 hours after randomizationFiO2 from ventilator settings
Peak PaCO2 in kPaDuring observation period; 1-6 hours after randomizationPaCO2 from arterial blood gasses
Nadir pHDuring observation period; 1-6 hours after randomizationpH from arterial blood gasses
Lung ultrasound aeration according to LUSDuring observation period; 1-6 hours after randomizationEvaluating lung aeration by Lung Ultrasound Score
Nadir PaO2-to-FiO2 ratioDuring observation period; 1-6 hours after randomizationCalculated by PaO2/FiO2. PaO2 from arterial blood gasses and FiO2 from ventilator setting

Other

MeasureTime frameDescription
Proportion of patients unable to tolerate observation period without increasing ventilator settingsDuring observation period; 1-6 hours after randomizationDefined as measures aimed at increasing either oxygenation or ventilation

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026